OPKO Health (OPK) raises $125M in senior secured notes tied to royalties
Rhea-AI Filing Summary
OPKO Health, Inc. entered into an amendment to its July 17, 2024 Note Purchase Agreement, issuing additional senior secured notes with an aggregate initial principal amount of $125,000,000. These Notes mature on July 17, 2044 and bear interest at the 3‑month SOFR, subject to a 4.0% per annum floor, plus 7.5% per annum, consistent with the existing notes.
Interest is payable quarterly and is determined by profit share payments EirGen Pharma Limited receives from Pfizer under a profit share arrangement. The Notes are secured by EirGen’s royalty interest in mazdutide under a license with Eli Lilly for sales in China, with related Mazdutide Payments capped at $187.5 million, subject to certain liabilities and expenses. Royalty and Mazdutide Payments are applied first to interest and then, if available, to principal reduction.
OPKO Biologics Ltd. and EirGen guarantee the obligations and have granted security interests in certain of their assets. The amended agreement includes customary negative and financial covenants and standard events of default. The Additional Notes were privately placed under exemptions from Securities Act registration.
Positive
- Company secures $125,000,000 in additional long-term funding without immediate equity dilution, tied to specific royalty and profit share cash flows.
- Interest and principal are serviced primarily from Royalty Payments and capped $187.5 million Mazdutide Payments, aligning debt service with related revenue streams.
Negative
- New $125,000,000 senior secured notes at SOFR plus 7.5% (with a 4.0% SOFR floor) add high-cost, long-dated leverage.
- Notes are secured by key royalty and Mazdutide Payment streams (capped at $187.5 million) and subject to financial covenants and default provisions, increasing creditor claims and compliance risk.
Filing Explained
OPKO has issued the
8-K Event Classification
3 items: 1.01, 2.03, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Additional Notes Principal: $125,000,000
Note Maturity Date: July 17, 2044
SOFR Interest Floor: 4.0% per annum
+2 more
5 metrics
Additional Notes Principal
$125,000,000
Aggregate initial principal amount of additional senior secured notes issued under the amended agreement
Note Maturity Date
July 17, 2044
Maturity date for the Notes issued under the Original and Amended Agreements
SOFR Interest Floor
4.0% per annum
Minimum 3‑month SOFR rate used to calculate the Notes’ interest
Interest Margin
7.5% per annum
Margin added to 3‑month SOFR (subject to floor) for the Notes’ interest rate
Mazdutide Payment Cap
$187.5 million
Maximum Mazdutide Payments applied, subject to indemnified liabilities and expenses
Key Terms
Note Purchase Agreement, senior secured notes, Royalty Payments, Mazdutide Payments, +1 more
5 terms
Note Purchase Agreement financial
"entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024"
A note purchase agreement is a contract where an investor buys a company’s promissory note — essentially an IOU promising repayment with interest — instead of buying equity. It matters to investors because it defines the borrower’s repayment schedule, interest rate and legal protections, so it affects expected returns, risk of loss, and where the investor stands compared with shareholders or other creditors if the company runs into trouble.
senior secured notes financial
"pursuant to which the Company issued additional senior secured notes (the “Additional Notes”)"
Senior secured notes are loans a company sells to investors that are backed by specific assets and given first priority for repayment if the company defaults. Because they have a claim on collateral and are paid before other debts, they usually offer lower risk and correspondingly lower interest than unsecured debt; investors use them to judge how safe repayment and recovery of principal might be, like holding a mortgage instead of an unsecured credit card balance.
Royalty Payments financial
"profit share payments received by EirGen pursuant to the profit share arrangement with Pfizer, Inc. (the “Royalty Payments”)"
Payments made to the owner of an asset, patent, trademark, mineral right, or creative work in exchange for permission to use it; they are typically a percentage of sales or a fixed fee per unit sold. For investors, royalty payments represent a steady income stream tied to the underlying product’s sales performance, similar to collecting rent from tenants — predictable cash flow that can reduce risk or add value when evaluating a company’s revenue sources.
Mazdutide Payments financial
"EirGen receives royalty payments for sales of mazdutide in China (“Mazdutide Payments”)"
financial covenants financial
"The Amended Agreement also contains financial covenants, customary events of default"
Financial covenants are rules written into loan or bond agreements that require a company to keep certain financial measures within agreed limits—examples include minimum cash, maximum debt levels, or minimum profit margins. They act like guardrails for lenders: breaking a covenant can force renegotiation, trigger penalties or default, and quickly affect a company’s available cash and stock value, so investors watch them as early warning signs of financial stress.
FAQ
What did OPKO (OPK) announce regarding new debt financing?
OPKO entered an amended Note Purchase Agreement and issued $125,000,000 in additional senior secured notes. These notes extend existing financing and are backed by royalty and Mazdutide Payment streams tied to EirGen’s arrangements with Pfizer and Eli Lilly.
What are the interest terms on OPKO’s new $125 million notes?
The additional notes bear interest at the 3‑month SOFR with a 4.0% floor plus 7.5% per annum. Interest is payable quarterly and is funded first from EirGen’s profit share payments received from Pfizer before drawing on Mazdutide Payments.
When do OPKO’s new senior secured notes mature?
The additional senior secured notes issued under the amended agreement mature on July 17, 2044. This long-dated maturity aligns the financing with the expected life of the underlying royalty and Mazdutide Payment streams that secure the notes.
What collateral secures OPKO’s new $125 million notes?
The notes are secured by Royalty Payments and Mazdutide Payments paid to EirGen, including mazdutide royalties under Eli Lilly’s China license. Mazdutide Payments applied are capped at $187.5 million, subject to specified liabilities and expenses.
Who guarantees OPKO’s amended note obligations?
OPKO’s wholly owned subsidiaries OPKO Biologics Ltd. and EirGen Pharma Limited guarantee the obligations. They granted security interests in certain of their assets, and the agreement includes negative and financial covenants plus customary events of default.
How were OPKO’s new notes under the amended agreement offered?
The Additional Notes were privately placed under Section 4(a)(2) of the Securities Act and Rule 144. Purchasers are accredited investors or qualified institutional buyers, acquiring the notes for investment, with restrictive legends on the securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
